Can You Take Amlodipine at Night? What the Timing Trials Show

Evidence check: Rebuilt August 29, 2026 from current U.S. amlodipine labeling and primary timing trials. Medical review is pending; this is not an individualized instruction to move a prescribed dose.

The short answer hides three different decisions

Someone asking “Can I take amlodipine at night?” may be asking one of three questions:

1. Is bedtime permitted? Yes. The current label says to take amlodipine once daily, with or without food, and gives breakfast, dinner, or bedtime as examples of a consistent routine [1].
2. Should a stable morning dose be moved? Not simply because bedtime sounds more scientific. Large outcome trials did not find that routine evening or bedtime dosing prevented more major cardiovascular events [2,3].
3. Could timing matter for this particular person? Possibly—especially when a symptom reliably follows the dose, the medication schedule is hard to follow, or 24-hour ambulatory monitoring identifies a specific overnight pattern. That is an individualized regimen question, not a universal chronotherapy rule.

Those answers can coexist. Nighttime administration is valid; nighttime superiority is unproven; and an individual plan can still have a reason for choosing one time over another.

Why amlodipine is unusually forgiving about the clock

Amlodipine is absorbed gradually. The label reports peak blood concentrations about 6 to 12 hours after a dose and a terminal elimination half-life of roughly 30 to 50 hours [1]. With daily use, steady state is generally reached after 7 to 8 days.

That long half-life creates overlap: when today’s dose is taken, a meaningful amount from earlier doses remains. It also helps explain why clinical studies found blood-pressure lowering across the 24-hour dosing interval, with relatively little difference between peak and trough effect [1].

This pharmacology supports flexibility; it does not make timing irrelevant in every situation. Two boundaries matter:

• A population half-life is not permission to improvise alternate-day dosing or repeatedly swing between morning and night.
• Long duration does not prove that every person has equally controlled pressure during sleep, on waking, and late in the dosing interval.

Clock time is therefore a fine-tuning variable, not the main measure of whether treatment is working. Blood-pressure response, symptoms, and adherence carry more information.

What the trials answer—and what they do not

Timing studies often get flattened into a headline. In practice, they answer different questions.

The evidence is not contradictory once the endpoints are kept separate. A schedule can move a nighttime reading without producing a demonstrated reduction in cardiovascular events.

TIME: no outcome advantage to routine evening dosing

The UK TIME trial randomized 21,104 adults with hypertension to take their usual antihypertensive medicines in the morning or evening [2]. Over a median 5.2 years, the primary composite of vascular death or hospitalization for nonfatal myocardial infarction or nonfatal stroke occurred in 3.4% of the evening group and 3.7% of the morning group. The unadjusted hazard ratio was 0.95 (95% CI 0.83–1.10; P=0.53).

Small home-reading differences did appear in opposite directions depending on when the reading was taken. That nuance is useful: timing may shift the curve a little, yet the trial still found no cardiovascular advantage.

The TIME Study authors summarized the outcome directly: “Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes.” That statement applies to the trial's usual-antihypertensive regimens; it is not an amlodipine-only finding or permission to ignore a prescribed divided schedule [2].

TIME was pragmatic and regimen-level. It was not an amlodipine monotherapy trial, and it excluded people taking antihypertensives at multiple daily times and regular overnight-shift workers. It should not be stretched into an answer for every circadian or occupational schedule.

BedMed: a second large trial reached the same practical result

BedMed randomized 3,357 Canadian primary-care adults and followed them for a median 4.6 years [3]. The composite of all-cause death or hospital/emergency care for stroke, acute coronary syndrome, or heart failure occurred at 2.3 events per 100 patient-years with bedtime dosing and 2.4 with morning dosing (adjusted hazard ratio 0.96; 95% CI 0.77–1.19; P=0.70).

Falls or fractures, new glaucoma diagnoses, and measured cognitive decline also did not differ materially. Calcium-channel blockers made up 29% of baseline antihypertensive use, but the study moved whole once-daily regimens; it did not isolate amlodipine.

One overlooked result belongs in the adherence conversation. At six months, 83% of once-daily drugs assigned to bedtime and 95% assigned to morning were reportedly taken at the allocated time [3]. This does not establish that mornings are universally easier. It does show why a theoretically attractive schedule can lose value if it fits poorly into real life.

Why older bedtime advice sounded more certain

Earlier MAPEC and Hygia publications reported unusually large cardiovascular benefits from bedtime dosing and helped turn chronotherapy into a broad online rule. A 2022 International Society of Hypertension position paper reviewed that literature, identified major methodological concerns and high risk of bias, and advised against routinely preferring bedtime treatment while independent outcome evidence was still pending [4]. TIME and BedMed later supplied that independent evidence and did not reproduce an outcome advantage.

That history explains why two accurate statements are often blurred together: nighttime blood pressure can carry prognostic information, but simply moving every prescription to bedtime has not been shown to improve prognosis.

Amlodipine-specific evidence is smaller and more mixed

A 2003 double-blind crossover study compared 7 a.m. with 9 p.m. amlodipine in 62 adults with mild-to-moderate hypertension [5]. In that small study, morning dosing produced a greater nocturnal BP fall, while 24-hour diastolic BP load and nighttime BP load were higher with evening dosing. The result runs directly against the idea that “later must be better,” but it came from a short, single study with dose titration and no cardiovascular outcome endpoint.

A later trial of an amlodipine/valsartan combination found broadly similar 24-hour, daytime, and nighttime control with morning and evening administration, with small differences in selected measures [6]. Because valsartan was part of the tablet, the result cannot be attributed to amlodipine alone.

The 2025 OMAN trial adds newer evidence but needs the same discipline [7]. It randomized 720 adults to morning or bedtime treatment with a single pill containing olmesartan 20 mg and amlodipine 5 mg. After 12 weeks, the bedtime group had a 3.0 mm Hg greater reduction in nighttime systolic pressure and a 1.4 mm Hg greater reduction in nighttime diastolic pressure. The study tested a two-drug regimen, adjusted treatment based on ambulatory and office readings, lasted three months, and did not measure cardiovascular events.

OMAN is a reason to investigate targeted timing—not a reason for every person taking amlodipine to move it to bed.

The Amlodipine Timing Problem Map

Before moving the dose, identify which problem the clock change is supposed to solve.

This map prevents a common error: treating timing preference, medication adherence, blood-pressure pattern, and adverse effects as if they were one problem.

Consistency matters, but “the exact same minute” does not

The label’s practical advice is to use the same time each day because routine makes dosing easier [1]. For many people, the strongest anchor is not a number on the clock but an event that reliably happens: breakfast, brushing teeth, dinner, or getting ready for bed.

That does not mean a small delay converts amlodipine into a missed dose. Its long half-life gives it a broad pharmacologic tail. It does mean that frequent back-and-forth switching makes it harder to know whether a symptom, reading, or skipped tablet reflects the drug or the schedule.

If inconsistency is the problem, the best schedule is the one that survives weekends, travel, late meals, and ordinary disruption. For questions about an actual forgotten tablet, use the amlodipine missed-dose guide; a planned clock change and a missed dose are not the same event.

Nighttime blood pressure is a measurement question first

Blood pressure normally changes across wakefulness and sleep. Some people show reduced nighttime dipping or pressure that remains high during sleep. These patterns matter, but an office reading cannot reveal them, and a single high reading on waking does not prove what happened overnight.

A 24-hour ambulatory blood-pressure monitor records measurements during ordinary activity and sleep. When nocturnal hypertension is the reason for considering bedtime medication, that profile is more informative than guessing from the clock. The result may lead to a time change, a dose or drug change, a review for sleep apnea, or another intervention.

Home readings remain useful for the broader response. The amlodipine monitoring guide explains how to build a repeatable record instead of comparing readings taken under different conditions.

Edema and dizziness need different reasoning

Ankle swelling is dose-related, not proven clock-related

In placebo-controlled label data, edema occurred in 1.8% at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg, compared with 0.6% with placebo [1]. That dose gradient is strong evidence. Comparable evidence that bedtime dosing makes edema go away does not exist.

A person may notice more swelling late in the day because gravity and time upright affect fluid distribution. Moving the tablet to bedtime does not necessarily address the vascular mechanism behind amlodipine edema. Persistent symmetrical swelling can prompt dose or regimen review. New one-sided, painful, red, rapidly worsening swelling—or swelling with shortness of breath or chest pain—should not be handled as a dosing-time experiment.

Dizziness needs a timeline, not an assumption

The label reports dizziness in 3.4% of people taking 5 or 10 mg versus 1.5% with placebo [1]. But feeling dizzy “in the morning” does not prove a morning dose caused it. The relevant sequence is: dose time, symptom time, posture, blood-pressure and pulse reading if available, food and fluid intake, and other medicines.

Taking a dose at bedtime may move the symptom window for some people; it may also place blood-pressure lowering during nighttime bathroom trips in someone prone to falls. Review the amlodipine adult safety guide for the difference between common effects and symptoms that deserve quicker attention. When another medicine may be adding to low pressure or edema, the amlodipine interaction guide is the more relevant next page.

The one-page Clock-Change Brief

A useful conversation with a pharmacist or prescriber does not need a week of perfect data. It does need more than “night seems better.” Write down:

This brief is deliberately not a universal switching schedule. The transition depends on the current dose, the old and new times, other medicines, and why the change is being made.

Changing from morning to night

Do not take two doses together to force the clock forward. The current label tells patients not to take more than one dose at a time [1]. It does not publish one universal morning-to-night conversion schedule.

A pharmacist or prescriber can give a one-time transition instruction without changing the prescription itself. That check becomes more important when readings run low, dizziness or falls are present, several blood-pressure medicines are used, liver function is impaired, or amlodipine is being used for angina rather than hypertension alone.

Also avoid changing multiple variables at once. Moving amlodipine, changing the dose, starting a supplement, and altering another medicine on the same day makes the result nearly impossible to interpret.

Bottom line

Amlodipine can be taken at night, and the current patient instructions say so. But the strongest modern outcome evidence does not support moving every antihypertensive regimen to bedtime. Amlodipine’s long half-life makes morning, dinner, or bedtime workable for many people.

The decision improves when the question is made specific: Is the goal better adherence, investigation of a symptom, or treatment of a measured 24-hour blood-pressure pattern? Bedtime may be a good routine. It is not a universal treatment upgrade, a proven fix for ankle swelling, or a substitute for ambulatory evidence and regimen review.